First-generation GLP-1 receptor agonist (Victoza/Saxenda). Once-daily injectable studied extensively for T2D glycemic control and obesity. Foundational molecule in the GLP-1 research class.
Liraglutide is a GLP-1 receptor agonist that predates semaglutide as the first GLP-1 medication approved specifically for obesity (Saxenda). It is also approved for type 2 diabetes (Victoza). While it has been largely superseded by semaglutide for weight management due to its lower efficacy and need for daily injection versus weekly, it has extensive clinical trial data and a well-established safety record.
Type 2 Diabetes Management
Liraglutide is approved for type 2 diabetes and has a substantial evidence base. The LEADER trial showed that daily liraglutide reduced cardiovascular events in high-risk diabetes patients by 13% compared to placebo — the first cardiovascular outcomes trial win for a GLP-1 compound.
Obesity and Weight Management
The SCALE trial program studied liraglutide 3.0mg daily for obesity. Mean weight loss was around 8% of body weight, which supported approval for chronic weight management. This was a meaningful result, though smaller than what later semaglutide trials achieved.
Cardiovascular Outcomes
The LEADER trial was a landmark cardiovascular outcomes trial in type 2 diabetes patients, showing a reduction in major adverse cardiovascular events. This established cardiovascular benefit for the GLP-1 class in high-risk populations.
Pediatric Obesity
Liraglutide was studied and approved for use in adolescents aged 12-17 with obesity, making it one of the few approved obesity treatments in this age group.
LEADER trial: 13% reduction in cardiovascular events in high-risk type 2 diabetes patients.
SCALE trials: approximately 8% weight loss at the 3.0mg dose over 56 weeks.
FDA-approved for type 2 diabetes and for chronic weight management.
Approved for adolescent obesity (age 12+), expanding its use beyond adults.
Well-tolerated overall; GI side effects are the most common issue.
Liraglutide requires daily injection, unlike weekly semaglutide or tirzepatide. Its weight loss magnitude (average 8%) is lower than later GLP-1 class compounds, making it a less preferred option for weight management in most current clinical contexts. GI side effects are common at initiation. It shares the class warning about thyroid C-cell tumors from rodent studies.
Liraglutide is a version of the natural GLP-1 hormone modified with a fatty acid chain that allows it to bind to albumin in the blood. This attachment slows its clearance, extending its half-life from 2 minutes (natural GLP-1) to about 13 hours, which is enough for once-daily dosing. By activating the GLP-1 receptor continuously throughout the day, it reduces appetite, slows stomach emptying, and improves insulin secretion in response to meals. The mechanism is the same as other GLP-1 agonists, but the modifications that give it its duration are simpler than the more elaborate engineering behind semaglutide's week-long half-life.
FDA-approved with extensive safety data from large long-term trials including LEADER. The most common side effects are GI — nausea, vomiting, diarrhea — typically most pronounced when starting or increasing dose. Carries a boxed warning about thyroid C-cell tumors from rodent studies; the human relevance is not established but it is contraindicated in people with personal or family history of medullary thyroid carcinoma or MEN2. Rare cases of pancreatitis have been reported. Requires prescription and medical supervision.
High Evidence
This compound has been studied in multiple large randomized controlled trials with human subjects. The evidence base is strong and consistent across independent research groups.
Published Research Ranges
0.6–1.8mg/day for T2D research; 3.0mg/day for obesity endpoint studies (SCALE trials)
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)
New England Journal of Medicine • 2016
• DOI: 10.1056/NEJMoa1603827
Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test
Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial
Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis
Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.